| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | istradefylline | CTRPv2 | pan-cancer | AAC | 0.0075 | 0.9 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.9 |
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | Compound 7d-cis | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |